Related Experiment Video
Updated: Aug 13, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive
1Department of Medicine, University of Witwatersrand, Johannesburg, South Africa. touyzr@ircm.qc.ca
Abstract:
This study evaluated the effects of magnesium supplementation on the development of hypertension in spontaneously hypertensive rats (SHR) and assesses the actions of magnesium on extracellular and intracellular Ca2+, Na+, and K+ status. Ten-week-old SHR (n = 72) and Wistar-Kyoto rats (WKY) (n = 60) were divided into four groups: WKY, Mg-WKY (WKY receiving 650 mg/L Mg(2+)supplementation), SHR, and Mg-SHR (SHR receiving Mg2+). Rats were studied for 17 weeks. Serum and erythrocyte Mg2+ and Ca2+ (measured by atomic absorption spectroscopy) and Na+ and K+ (measured by flame photometry) were determined every 3 or 4 weeks. From 13 weeks of age, blood pressure (BP) was significantly elevated in SHR compared with age-matched WKY. BP was reduced (P < .01) in SHR after 10 weeks of Mg2+ supplementation and at 27 weeks of age, BP in SHR was 218 (12 mm Hg v 184 +/- 9 mm Hg) in Mg-SHR. From 18 weeks of age, serum and intracellular Mg2+ levels were significantly lower (P < .05) and from 21 weeks of age, erythrocyte Ca2+ was significantly higher in SHR than in WKY. Mg2+ supplementation normalized intracellular Mg2+ and Ca2+ concentrations in SHR. BP was inversely correlated with erythrocyte Mg2+ (r = -0.74, P < .01) and positively correlated with erythrocyte Ca2+ (r = 0.78, P < .001). In conclusion, long-term Mg2+ supplementation significantly attenuates, but does not prevent, the development of hypertension in SHR. Furthermore, intracellular Mg2+ deficiency and Ca2+ overload in SHR are normalized by Mg2+ treatment.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

